for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AstraZeneca's diabetes drug shows benefit in late-stage study in adolescents

AstraZeneca Plc’s diabetes drug significantly reduced blood sugar levels in a late-stage study in adolescents aged 10–17 with type 2 diabetes, the UK-based drugmaker said on Friday.

Data from the study was presented at the 2021 American Diabetes Association (ADA) Virtual 81st Scientific Sessions. (Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up